Background and purpose: The aim of this study was to analyse the clinical and prognostic features of myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination with different onset phenotypes. , n = 14) and (iv) both ON and TM at onset (n = 3). This final group was not included in further analyses. Data were collected through medical records and regular follow-up. Results: Median age at presentation was 24 (range, 3-63) years in the whole cohort (50% female). MOG-ON À -TM À patients had the youngest age of onset across the three groups. Patients with MOG-TM + tended to relapse more frequently and had a longer interval to first relapse than was observed in MOG-ON + and MOG-ON À -TM À patients. High MOG-IgG titres were associated with increased cerebrospinal fluid leukocytes. The likelihood of harbouring transient, low MOG-IgG titres was higher in the MOG-TM + group than in the other groups. After a median disease duration of 20 months, most but not all cases had a favourable outcome, with 8% developing severe visual deficit, 2% becoming wheelchair-dependent and 6% developing cognitive impairment. The onset phenotype appeared to be an important predictor of disability type. Having high MOG-IgG titres (odds ratio, 0.168, P = 0.027) or female gender (odds ratio, 0.270, P = 0.067) was associated with a lower likelihood of complete recovery. Conclusions: Onset phenotype may influence long-term presentation, MOGIgG status as well as outcome. Further large and prospective studies are needed to better clarify the clinical implications of the first demyelinating event.
Introduction
Myelin oligodendrocyte glycoprotein (MOG) is a component of myelin sheaths that is solely expressed in the central nervous system, which has been thought to be an important target of inflammatory demyelinating disorders. Mounting evidence demonstrates that serum immunoglobulin against MOG (MOG-IgG) could be detected in a subset of patients with monophasic or multiphasic acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis (TM), aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) [1, 2] .
The prevalence of MOG-IgG differs depending on age, showing that children are more likely to harbour this antibody than adults, and disease classification, which is often associated with a non-MS course [1, 3] . Clinical phenotype appears to be age-dependent with younger patients being more likely to exhibit encephalopathy and older patients showing ON [4, 5] . As a broad clinical spectrum of disease entities, variable signs of onset potentially pose a challenge to early diagnosis and treatment of MOG antibody-associated demyelination. More recently, a UK study identified that onset attack with TM was a risk factor for long-term disability, emphasizing the importance of first manifestation to the whole disease course and future prognosis [4] .
In this study, we described and compared the demographic, clinical and outcome characteristics among MOG-IgG-seropositive patients who initially presented with ON, TM or pure brain symptoms and tested the clinical relevance of MOG-IgG through a longitudinal analysis.
Methods

Patients and samples
This study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Written consent was obtained from all participants.
We retrospectively reviewed patients with central nervous system acquired demyelinating syndromes in the Multiple Sclerosis Center of the Third Affiliated Hospital of Sun Yat-sen University from September 2013 to June 2017. Available serum samples from 715 patients were analysed in a single centre for the presence of MOG-IgG and AQP4-IgG. Clinical data were collected through our medical records and regular follow-ups.
Laboratory testing
Serum MOG-IgG and AQP4-IgG were detected as described elsewhere [e1] (Appendix S1). To determine the coexistence of MOG-IgG and AQP4-IgG, sera were collected at the same time and retested if necessary. Initial cerebrospinal fluid (CSF) samples were taken during acute presentation prior to steroid therapy.
Outcome
For patients with previous ON episodes, visual acuity (VA) (Snellen) at the first ON attack as well as at the final visit (time after ON onset: mean, 22.2 months; median, 15 months; range, 2-116 months) was measured and classified into the following four grades: severe (VA ≤ 6/60), intermediate (6/12 ≤ VA < 6/60), mild (VA > 6/12) and normal. Residual disability was assessed at last follow-up based on the Expanded Disability Status Scale score.
Statistical analysis
All statistical analyses and figures were conducted on SPSS version 22.0 (SPSS, Chicago, IL, USA) and Prism software version 6.0 (GraphPad Software, La Jolla, CA, USA). Fisher's exact test, Kruskal-Wallis test and Mann-Whitney U-test were used when comparing differences between groups.
The associations between MOG-IgG titres and age of onset or CSF parameters were assessed using Spearman's correlation coefficients. A Kaplan-Meier analysis was used to estimate time to first relapse. Survival curves between groups were compared using the log-rank test. Univariable and multivariable logistic regression models were performed to identify factors associated with a complete recovery. A two-sided P < 0.05 was considered statistically significant.
Results
Patient groups
In total, 7.2% (52/715) of the patients with central nervous system acquired demyelinating syndromes were MOG-IgG-positive (Fig. 1a) . Based on their initial phenotypes, 52 MOG-IgG-positive patients were divided into four groups as follows: (i) , but the differences did not reach significance (Fig. S1 ). As shown in Table 1 , approximately 20-30% of the patients exhibited clinical evidence of other attack localizations in addition to the initial one (i.e. optic nerve, spinal cord and brain).
Optic neuritis remained dominant (40%) when considering the detailed clinical events of all 130 episodes in the three analysed groups of patients (Fig. 2 ). There were some differences with regard to the frequency of events, with unilateral ON and myelitis mainly reported in patients with MOG-ON + (23%) and MOG-TM + (26%), respectively, whereas supratentorial encephalitis was the most common presentation in patients with MOG-ON À -TM À (24%).
Laboratory results
Baseline samples for serum MOG-IgG were taken at the time of acute presentation with a median interval of 6.5 (range, 0.5-112) months from the first attack. High MOG-IgG titres were associated with increased CSF leukocytes (Spearman r = 0.642, P < 0.001). coexistence of MOG-IgG and AQP4-IgG was documented in one MOG-ON + patient. In this subject, the levels of both antibodies (baseline: MOG-IgG, 1:320; AQP4-IgG, 1:320) were temporarily lower (MOG-IgG to undetectable; AQP4-IgG to 1:50) after treatment with plasma exchange and intravenous methylprednisolone but were subsequently higher at the final testing (MOG-IgG, 1:100; AQP4-IgG, 1:100).
Most laboratory findings were similar across three groups. There was a higher frequency of concomitant autoantibodies in MOG-TM + than in MOG-ON + (P = 0.031).
Treatment and outcomes
All cases received intravenous methylprednisolone during acute attacks, with improvements in 51/52 and additional intravenous immunoglobulin (IVIg) or plasma exchange was used in 11 cases, with improvements in 11/11. Preventive therapies are listed in Table 1 . Three children (one with NMOSD, two with MS) with high MOG-IgG titres (range, 1:320-1:1280) switched to rituximab (n = 2) and azathioprine (n = 1) due to treatment failure of initial modifying therapies (including azathioprine, mycophenolate mofetil and interferon-beta; one case reported previously). After a median disease duration of 20 (range, 2-118) months, 12/22 (55%) patients with MOG-ON + achieved a complete recovery, whereas only 3/12 (25%) patients with MOG-TM + and 6/14 (43%) patients with MOG-ON À -TM À (Fig. 2 ) did so. The first ON attack was severe in 59% (17/29), intermediate in 10% (3/29) and mild in 31% (9/29). Motor disability with limitations but not requiring a cane/aids, was more common in MOG-TM + than in MOG-ON + (P = 0.012). A logistic regression (Table 2) indicated that female gender (odds ratio, 0.270; 95% confidence interval, 0.067-1.096, P = 0.067) or high MOG-IgG titre (odds ratio, 0.168; 95% confidence interval, 0.035-0.815, P = 0.027) indicated a lower likelihood of complete recovery. Residual cognitive problems were found in three MOG-ON À -TM À patients who presented with ADEM manifestations at disease onset.
Neuroimaging findings
Results of brain and spinal magnetic resonance imaging scans closest to MOG-IgG testing are listed in Table 3 with representative images shown in Fig. 3 (68% and 50%, respectively; P < 0.05 vs.
MOG-ON
À -TM
À for both comparisons) of brain abnormalities than clinical features (30% and 25%, respectively). In addition, the frequency of longitudinally extensive transverse myelitis (maximal spinal length ≥ 3 vertebral segments), cervical and thoracic spinal lesions was significantly higher in the MOG-TM + group than in the MOG-ON + and MOG-ON
Brain lesions in all three groups tended to be fluffy, bilateral and multifocal, predominantly affecting the supratentorial and infratentorial white matter, perithird ventricle, thalamus and brainstem regions. Scattered dots or patches of white matter lesions were the most common abnormalities and these did not usually result in seizures or other clinical symptoms. Notably, over half of the MOG-ON À -TM À patients (57%) had extensive brain lesions, whereas only 5% of the MOG-ON + and 8% of the MOG-TM + patients did so (P < 0.05 and P < 0.001, respectively).
Discussion
The main findings of our study include the following: (i) most episodes of MOG-IgG-associated demyelination, including those occurring at onset or throughout the course, are accompanied by ON; (ii) the majority of, but not all, affected patients can benefit from appropriate treatment strategies and the onset phenotype seems to be an important predictor of disability type; (iii) male gender and a low MOG-IgG titre are associated with a complete recovery; and (iv) whereas MOG-IgG appears to be pathogenic, patients with TM at onset tend to harbour transient, low MOGIgG levels but have a higher relapse frequency and a poorer prognosis. This last finding requires further study.
To date, the pathogenicity of human antibodies to MOG remains a matter of debate. An increasing number of in-vitro and in-vivo studies have shown a demyelinating effect induced by human MOG-IgG through activating complement [e5], directly damaging the myelin [e6] or affecting oligodendrocyte cytoskeletons [e7]. In our cohort, patients tended to exhibit increased intrathecal inflammation and incomplete recovery in the context of high MOG-IgG titres. Patients with persistent MOG-IgG status were also more likely to relapse than those with transient MOG-IgG status. Moreover, antibody titres declined substantially from an acute attack to remission stage, indicating a relationship between MOG-IgG and disease activity. In line with other findings [1, 3, 6] , our results strongly argue against the notion that MOGIgG is a pure epiphenomenon that occurs secondary to myelin destruction. Interestingly, we observed parallel fluctuations of MOG-IgG and AQP4-IgG titres in a double-positive subject. Given that a sizeable proportion of our patients still harboured serum MOGIgG despite immunotherapies, as previously described in AQP4-IgG-positive NMOSD [e8], it is reasonable to assume that MOG-IgG, if pathogenic, may be able to trigger an acute demyelinating attack under certain conditions (e.g. an impaired blood-brain barrier). Consistent with previous reports [2, 4, 5, 7] , our study confirms that ON represents the most common phenotype at both onset and subsequent attacks. The preferential involvement of the optic nerve has also been noted in animal research, which found a dominant injury of the optic nerve after immunization with mouse MOG to produce features of experimental autoimmune encephalomyelitis [e15]. Among patients with previous ON, the first ON attack was often severe but generally had a favourable outcome. Several studies indicated that severe visual deficit occurred only in patients showing ON at onset [4, 7] . However, two cases in our study starting with a non-ON phenotype reached VA ≤ 6/60, which warrants more detailed investigation.
Patients with MOG-ON À -TM À had an earlier onset of disease and commonly showed an ADEM-like presentation. Similar to previous studies [6, 7] , we identified a sizeable proportion of patients presenting with ON or myelitis at onset who displayed abnormal brain magnetic resonance imaging results, which might be associated with onset severity and CSF pleocytosis [7] . Moreover, our study, together with others, observed large brain lesion in 12-52% of MOG-IgGpositive patients [2, 8] [e9]. Screening for MOG-IgG may thus be of diagnostic value when encountering a large cerebral lesion in any patient suspected of having a demyelinating disorder. A substantial proportion of our patients had recurrent episodes, which goes against the notion that MOG-IgG typically denotes a monophasic illness . By contrast, another study indicated that patients starting with ON were more likely to relapse than those starting with TM or ADEM [4] . These contradictory results may be attributable to the differences in ethnicity, grouping method, selection bias, follow-up duration and treatment effects. with TM was associated with lower levels of MOGIgG. Theoretically, if MOG-IgG is indeed pathogenic, patients with transient, low MOG-IgG titres should experience a monophasic and more benign disease course, but our current findings seem to challenge this assumption. Although the sample size and follow-up duration were not sufficient to draw a solid conclusion, we believe that factors other than MOG-IgG alone may have participated in disease induction and maintenance.
We observed an age-dependent phenotype, with brain manifestations mainly occurring in children and ON being the most common phenotype in adults, similar to previously reported findings [1, 2, 4, 5] . These findings probably reflect an age-dependent anatomical susceptibility to MOG-IgG at different stages of growth as the immune system, white matter and blood-brain barrier gradually mature from infancy to adulthood [e16,e17].
Most patients benefited from appropriate treatment strategies; however, three children did not respond well to baseline disease-modifying therapies [e13]. As increasing data report a high responsive to B-cell targeted therapy, IVIg and immunosuppressive agents in MOG-IgG-positive patients, prompt alternative strategies should be considered in those patients who are unresponsive to initial agents [5, 9, 10] [e13].
The prognosis of MOG antibody-associated demyelination remains controversial. Although initial data reported a milder and less-relapsing course in MOG-IgG-positive patients [8] [e10,e11], recent evidence demonstrates that this clinical spectrum is clearly more complicated. In our cohort, 8% of patients developed severe visual deficit, 2% became wheelchair-dependent and 6% were left with cognitive problems. By contrast, a previous study by Jarius et al. [6] indicated a poor outcome with 36% of patients showing severe visual loss and 25% having impaired ambulation. Some reports also emphasize that patients with MOG-IgG continue to relapse and accrue disability even under disease-modifying therapies [5, 9] . The majority of visual, motor and cognitive impairments were restricted to the MOG-ON + , MOG-TM + and MOG-ON À -TM À groups, respectively. In this regard, the onset phenotype appeared to be a useful indicator for predicting the type of disability. Our finding is reinforced by a recent study showing that most of the disability of MOG-IgG-positive patients was driven by the onset attack [4] . Using a multivariable logistic regression model, we found that high MOG-IgG titres and female gender indicated a lower likelihood of full recovery. The onset phenotype had a trend to influence the recovery A recent article has highlighted that the occurrence of TM at onset or during the course predicts the long-term disability [4, 5] . Having ON appeared to be protective with regard to neurological sequelae (defined as Expanded Disability Status Scale score ≥ 2) [5] . Given that the Expanded Disability Status Scale score might not be appropriate in assessing non-motor impairment, we believe that close attention should still be given to MOG-ON + individuals. Another concern is the subgroup with recurrent or bilateral ON as several studies reported persistently high titres of MOGIgG in these subjects, which may exert a direct effect on disease pathogenesis [6] [e14].
The present study has several limitations. Its limited sample size and follow-up duration somewhat restricted our ability to fully assess the above findings. In addition, recruiting patients from a single neurological centre could lead to a selection bias because the percentage of patients with pure visual symptoms may have been under-estimated. Also, our study contains a large age range and the sample size is therefore relatively small.
In summary, MOG-IgG-positive patients with different initial phenotypes differ markedly in their clinical presentations, laboratory results and recovery conditions. Further investigations will be needed to determine the clinical relevance of MOG-IgG and the long-term characteristics in this spectrum of disorders.
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